Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities:
Net loss	$ (44,306)	$ (17,684)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,886	4,912
Goodwill impairment charge	23,989	0
Non-cash lease expense	(227)	(160)
Change in fair value of warrant and derivative liabilities	(448)	(3,486)
Loss on derecognition of debt	0	2,985
Amortization of debt discount and issuance costs	0	5,398
Stock based compensation	3,520	3,316
Gain on license of patents, net	(198)	0
Loss on disposal of assets	0	12
Changes in operating accounts:
Accounts receivable	4,506	208
Prepaid expenses and other assets	315	220
Accounts payable and accrued liabilities	(1,375)	(2,224)
Other liabilities	(30)	553
Net cash used in operating activities	(9,368)	(5,950)
Investing activities:
Capital expenditures, net	(17)	(5)
Proceeds from license of patents, net	198	0
Other investing activities, net	0	71
Net cash provided by investing activities	181	66
Financing activities:
Proceeds from Common Stock, Warrants, and Pre-Funded Warrants Offering, net	3,351	0
Proceeds from financing arrangements	1,044	981
Repayments of financing arrangements	(829)	(1,156)
Other financing activities	5	15
Net cash provided by (used in) financing activities	3,571	(160)
Net decrease in cash and cash equivalents	(5,616)	(6,044)
Cash and cash equivalents, beginning of period	7,125	14,026
Cash and cash equivalents, end of period	1,509	7,982
Non-cash investing and financing activities:
Issuance of Common Stock in settlement and prepayment of notes payable	$ 0	$ 12,180